Health Tech Capitol | Erik Greenfield
7
archive,paged,author,author-egreenfield,author-7,paged-17,author-paged-17,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Author: Erik Greenfield

Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre...

Arrowhead Pharmaceuticals has finalized its agreement with Janssen Pharmaceuticals that’s worth $250 million for Arrowhead, just to start. The waiting period under the Hart-Scott Rodino Antitrust Act expired with no problems expressed by regulators, the companies said Wednesday. Janssen — part of the Johnson & Johnson conglomerate...

Xconomy Wisconsin — Invenra, a Madison, WI-based startup that develops therapeutic antibodies for pharmaceutical companies and other clients, has raised more than $7.1 million from investors, according to a regulatory filing. Twenty-three investors participated in the equity funding round, according to the filing, which was made public earlier this...